Bipolar Trans Carotenoid Salts for Respiratory Hypoxemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no known efficacious treatments for pneumonia caused by SARS coronavirus, MERS coronavirus, adenovirus, hantavirus, or parainfluenza, and existing methods for treating viral or bacterial-induced respiratory diseases with hypoxemia are inadequate.
Innovation Solution
Administration of a diffusion-enhancing compound, specifically bipolar trans carotenoid salts like trans sodium crocetinate (TSC), which increases oxygen diffusivity and is formulated with cyclodextrin for improved bioavailability, to treat and prophylaxis viral or bacterial-induced respiratory diseases, including COVID-19, pneumonia, and acute respiratory distress syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for viral or bacterial induced respiratory diseases, then standard care is provided, but there are no known efficacious treatments for pneumonia caused by SARS coronavirus, MERS coronavirus, adenovirus, hantavirus, or parainfluenza
Solution Approach 1:
The patent applies universality by developing a treatment approach using bipolar trans carotenoids that can be applied across multiple different viral infections (SARS coronavirus, MERS coronavirus, adenovirus, hantavirus, parainfluenza) and bacterial infections, rather than creating virus-specific treatments. The compound works through a general mechanism of enhancing oxygen diffusion that addresses the common pathological feature of hypoxemia across these different pathogens.
2Ease of operation
If supportive care is provided for viral pneumonia, then patient comfort is maintained, but treatment effectiveness is insufficient
Solution Approach 1:
The patent uses an intermediary substance (bipolar trans carotenoid) that mediates between the respiratory system and oxygen transport. The compound acts as a diffusion enhancer that facilitates oxygen transfer from the alveoli to the blood, addressing the fundamental oxygenation problem in viral pneumonia without requiring complex mechanical interventions.
3Reliability
If mechanical ventilation is used to treat hypoxemia, then oxygenation is improved, but patient morbidity and mortality remain high
Solution Approach 1:
The patent replaces the need for mechanical ventilation systems with a biochemical approach using bipolar trans carotenoids. Instead of using mechanical devices to force oxygen into the lungs and blood, the compound chemically enhances the natural diffusion process, substituting a complex mechanical system with a simpler molecular mechanism.
4Reliability
If extracorporeal membrane oxygenation is implemented, then severe hypoxemia is treated, but hospital stay duration and resource utilization increase
Solution Approach 1:
The patent applies preliminary action by administering bipolar trans carotenoids early in the course of respiratory infection to prevent the development of severe hypoxemia that would require ECMO. The compound is given before critical oxygenation failure occurs, addressing the underlying diffusion problem proactively rather than reacting to severe hypoxemia with complex life-support measures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of bipolar trans carotenoid salts enhances oxygenation in hypoxic conditions, reducing the need for mechanical ventilation and extracorporeal membrane oxygenation, improving blood oxygenation, and potentially reducing mortality and hospital stay duration in patients with severe respiratory infections.
Implementation Method 1
Carotenoids such as crocetin and trans sodium crocetinate (TSC) are known to increase the diffusivity of oxygen in water
Data Source
AI summary
The subject invention relates to novel methods for the treatment of viral or bacterial induced respiratory disease with hypoxemia.